Amendment: SEC Form SC 13G/A filed by Viatris Inc.

11/12/24 1:41:20 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VTRS alert in real time by email

SC 13G/A 1 VTRS13g093024.txt 3Q24 AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Viatris, Inc. -------------------------------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------------------------------- (Title of Class of Securities) 92556V106 -------------------------------------------------------------------------------- (CUSIP Number) September 30, 2024 -------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ------------------------------------------------------------------------------ ----------------------- CUSIP No. 92556V106 13G ----------------------- ------------------------------------------------------------------------------ 1. Name of Reporting Person I.R.S. Identification No. of above Person Davis Selected Advisers, L.P. 85-0360310 ------------------------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) [_] (b) [X] ------------------------------------------------------------------------------ 3. SEC Use Only ------------------------------------------------------------------------------ 4. Citizenship or Place of Organization Colorado Limited Partnership ------------------------------------------------------------------------------ 5. Sole Voting Power Number of 60,501,647 shares Shares ---------------------------------------------------------- 6. Shared or No Voting Power Beneficially 0 shares (Shared) Owned by 2,145,619 shares (No Vote) ---------------------------------------------------------- Each 7. Sole Dispositive Power Reporting 62,647,266 shares Person ---------------------------------------------------------- 8. Shared Dispositive Power With: 0 shares ------------------------------------------------------------------------------ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 62,647,266 shares ------------------------------------------------------------------------------ 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares n/a [_] ------------------------------------------------------------------------------ 11. Percent of Class Represented by Amount in Row (9) 5.9% ------------------------------------------------------------------------------ 12. Type of Reporting Person IA ------------------------------------------------------------------------------- Item 1(a). Name of Issuer: Viatris, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 1000 Mylan Boulevard Canonsburg, PA 15317 Item 2(a) and (b). Names and Principal Business Addresses of Persons Filing: Davis Selected Advisers, L.P. 2949 East Elvira Road, Suite 101 Tucson, Arizona 85756 Item 2(c). Citizenship: (1) Davis Selected Advisers, L.P. - Colorado Limited Partnership Item 2(d). Title of Class of Securities: Common Stock Item 2(e). CUSIP Number: 92556V106 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940. This statement is being filed by Davis Selected Advisers, L.P. as a registered investment adviser. All of the securities covered by this report are owned legally by Davis Selected Advisers, L.P.'s investment advisory clients and none are owned directly or indirectly by Davis Selected Advisers, L.P. As permitted by Rule 13d-4, the filing of this statement shall not be construed as an admission that Davis Selected Advisers, L.P. is the beneficial owner of any of the securities covered by this statement. -------------------------------------------------------------------------------- Item 4. Ownership. (a). Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b). Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c). Number of shares as to which such person has: (i). Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii). Shared or no power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii). Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv). Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (a) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Davis Selected Advisers, L.P. BY /s/ Michaela McLoughry PRINT Michaela McLoughry Vice President DATE November 8, 2024

Get the next $VTRS alert in real time by email

Recent Analyst Ratings for

$VTRS

Date	Price Target	Rating	Analyst
2/9/2026	$18.00	Neutral → Buy	UBS
1/16/2026	$15.00	Hold → Buy	Argus
12/9/2025	$15.00	Overweight	Barclays
10/15/2025	$15.00	Buy	Truist
6/6/2025	$10.00	Neutral	Goldman
7/19/2024	$15.00	Buy	Jefferies
10/23/2023	$13.00 → $9.00	Neutral → Underperform	BofA Securities
6/23/2023	$11.00	Equal Weight → Underweight	Barclays

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Viatris Inc.

11/12/24 1:41:20 PM ET

$VTRS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VTRS alert in real time by email

Recent Analyst Ratings for

$VTRS

Date	Price Target	Rating	Analyst
2/9/2026	$18.00	Neutral → Buy	UBS
1/16/2026	$15.00	Hold → Buy	Argus
12/9/2025	$15.00	Overweight	Barclays
10/15/2025	$15.00	Buy	Truist
6/6/2025	$10.00	Neutral	Goldman
7/19/2024	$15.00	Buy	Jefferies
10/23/2023	$13.00 → $9.00	Neutral → Underperform	BofA Securities
6/23/2023	$11.00	Equal Weight → Underweight	Barclays

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Viatris Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$VTRS

Amendment: SEC Form SC 13G/A filed by Viatris Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$VTRS

$VTRS
SEC Filings

SEC Form 10-K filed by Viatris Inc.

Viatris Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

$VTRS
Press Releases

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

$VTRS
Analyst Ratings

Viatris upgraded by UBS with a new price target

Viatris upgraded by Argus with a new price target

Barclays initiated coverage on Viatris with a new price target

$VTRS
Insider Trading

New insider Maletta Matthew Joseph claimed ownership of 25 shares (SEC Form 3)

Chief Financial Officer Mistras Theodora converted options into 25,260 shares and covered exercise/tax liability with 14,598 shares, increasing direct ownership by 42% to 35,842 units (SEC Form 4)

Chief Commercial Officer Le Goff Corinne sold $72,045 worth of shares (7,032 units at $10.25), decreasing direct ownership by 17% to 35,299 units (SEC Form 4)

$VTRS
Insider Purchases

Chief Executive Officer Smith Scott Andrew bought $219,740 worth of shares (22,000 units at $9.99), increasing direct ownership by 8% to 314,807 units (SEC Form 4)

Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

$VTRS
Financials

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

$VTRS
Large Ownership Changes